Last updated 42 days ago
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
1080 patients around the world
Available in Mexico
The study will enroll approximately 1080 patients randomized in a 1:1 ratio for
ivonescimab or pembrolizumab combined with platinum-doublet chemotherapy. The study will
enroll 45-50% of patients with NSCLC squamous histology and 50-55 % of patients with
NSCLC non-squamous histology.
Summit Therapeutics
1080Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Age ≥ 18 years old at the time of enrollment.Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.Expected life expectancy ≥ 3 months.Metastatic (Stage IV) NSCLC.Histologically or cytologically confirmed squamous or non-squamous NSCLC.Recorded measurement of the Tumor Proportion Score (TPS) for PD-L1 expression, irrespective of the PD-L1 expression, prior to randomization.At least one measurable noncerebral lesion according to RECIST 1.1.No prior systemic treatment for metastatic NSCLC.
- Histologic or cytopathologic evidence of the presence of small cell lung carcinoma.Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which first-line approved therapies are available.For non-squamous histology patients, actionable driver mutation testing results are required before randomization.Has received any prior therapy for NSCLC in the metastatic setting.Tumor invasion, encasement of organs (e.g. heart, trachea, esophagus, central bronchi), or major blood vessels (e.g aorta, central veins), if poses a significant increased risk of bleeding.
SponsorSummit Therapeutics
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05899608
